Cargando…
A Rapid Biochemical and Radiological Response to the Concomitant Therapy with Temozolomide and Radiotherapy in an Aggressive ACTH Pituitary Adenoma
Background and Importance. In the last eight years temozolomide (TMZ) has been used as the last-line treatment modality for aggressive pituitary tumors to be applied after the failure of surgery, medical therapy, and radiotherapy. The objective was to achieve a rapid control of tumor growth and horm...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5357528/ https://www.ncbi.nlm.nih.gov/pubmed/28357143 http://dx.doi.org/10.1155/2017/2419590 |
_version_ | 1782516055371939840 |
---|---|
author | Misir Krpan, Ana Dusek, Tina Rakusic, Zoran Solak, Mirsala Kraljevic, Ivana Bisof, Vesna Ozretic, David Kastelan, Darko |
author_facet | Misir Krpan, Ana Dusek, Tina Rakusic, Zoran Solak, Mirsala Kraljevic, Ivana Bisof, Vesna Ozretic, David Kastelan, Darko |
author_sort | Misir Krpan, Ana |
collection | PubMed |
description | Background and Importance. In the last eight years temozolomide (TMZ) has been used as the last-line treatment modality for aggressive pituitary tumors to be applied after the failure of surgery, medical therapy, and radiotherapy. The objective was to achieve a rapid control of tumor growth and hormone normalization with concurrent chemoradiotherapy in a patient with very aggressive ACTH pituitary adenoma. Clinical Presentation. We describe a patient with an aggressive ACTH-producing adenoma treated with concurrent temozolomide and radiotherapy. The patient suffered from an aggressive ACTH adenoma resistant to surgical and medical treatment. After two months of concurrent temozolomide and radiotherapy, cortisol normalization and significant tumor shrinkage were observed. After 22 months of follow-up, there is still no evidence of tumor recurrence. Conclusion. Concurrent treatment with temozolomide and irradiation appears to be highly effective in the achievement of the tumor volume control as well as in the control of ACTH secretion in aggressive ACTH adenoma. |
format | Online Article Text |
id | pubmed-5357528 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | Hindawi |
record_format | MEDLINE/PubMed |
spelling | pubmed-53575282017-03-29 A Rapid Biochemical and Radiological Response to the Concomitant Therapy with Temozolomide and Radiotherapy in an Aggressive ACTH Pituitary Adenoma Misir Krpan, Ana Dusek, Tina Rakusic, Zoran Solak, Mirsala Kraljevic, Ivana Bisof, Vesna Ozretic, David Kastelan, Darko Case Rep Endocrinol Case Report Background and Importance. In the last eight years temozolomide (TMZ) has been used as the last-line treatment modality for aggressive pituitary tumors to be applied after the failure of surgery, medical therapy, and radiotherapy. The objective was to achieve a rapid control of tumor growth and hormone normalization with concurrent chemoradiotherapy in a patient with very aggressive ACTH pituitary adenoma. Clinical Presentation. We describe a patient with an aggressive ACTH-producing adenoma treated with concurrent temozolomide and radiotherapy. The patient suffered from an aggressive ACTH adenoma resistant to surgical and medical treatment. After two months of concurrent temozolomide and radiotherapy, cortisol normalization and significant tumor shrinkage were observed. After 22 months of follow-up, there is still no evidence of tumor recurrence. Conclusion. Concurrent treatment with temozolomide and irradiation appears to be highly effective in the achievement of the tumor volume control as well as in the control of ACTH secretion in aggressive ACTH adenoma. Hindawi 2017 2017-03-05 /pmc/articles/PMC5357528/ /pubmed/28357143 http://dx.doi.org/10.1155/2017/2419590 Text en Copyright © 2017 Ana Misir Krpan et al. https://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Case Report Misir Krpan, Ana Dusek, Tina Rakusic, Zoran Solak, Mirsala Kraljevic, Ivana Bisof, Vesna Ozretic, David Kastelan, Darko A Rapid Biochemical and Radiological Response to the Concomitant Therapy with Temozolomide and Radiotherapy in an Aggressive ACTH Pituitary Adenoma |
title | A Rapid Biochemical and Radiological Response to the Concomitant Therapy with Temozolomide and Radiotherapy in an Aggressive ACTH Pituitary Adenoma |
title_full | A Rapid Biochemical and Radiological Response to the Concomitant Therapy with Temozolomide and Radiotherapy in an Aggressive ACTH Pituitary Adenoma |
title_fullStr | A Rapid Biochemical and Radiological Response to the Concomitant Therapy with Temozolomide and Radiotherapy in an Aggressive ACTH Pituitary Adenoma |
title_full_unstemmed | A Rapid Biochemical and Radiological Response to the Concomitant Therapy with Temozolomide and Radiotherapy in an Aggressive ACTH Pituitary Adenoma |
title_short | A Rapid Biochemical and Radiological Response to the Concomitant Therapy with Temozolomide and Radiotherapy in an Aggressive ACTH Pituitary Adenoma |
title_sort | rapid biochemical and radiological response to the concomitant therapy with temozolomide and radiotherapy in an aggressive acth pituitary adenoma |
topic | Case Report |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5357528/ https://www.ncbi.nlm.nih.gov/pubmed/28357143 http://dx.doi.org/10.1155/2017/2419590 |
work_keys_str_mv | AT misirkrpanana arapidbiochemicalandradiologicalresponsetotheconcomitanttherapywithtemozolomideandradiotherapyinanaggressiveacthpituitaryadenoma AT dusektina arapidbiochemicalandradiologicalresponsetotheconcomitanttherapywithtemozolomideandradiotherapyinanaggressiveacthpituitaryadenoma AT rakusiczoran arapidbiochemicalandradiologicalresponsetotheconcomitanttherapywithtemozolomideandradiotherapyinanaggressiveacthpituitaryadenoma AT solakmirsala arapidbiochemicalandradiologicalresponsetotheconcomitanttherapywithtemozolomideandradiotherapyinanaggressiveacthpituitaryadenoma AT kraljevicivana arapidbiochemicalandradiologicalresponsetotheconcomitanttherapywithtemozolomideandradiotherapyinanaggressiveacthpituitaryadenoma AT bisofvesna arapidbiochemicalandradiologicalresponsetotheconcomitanttherapywithtemozolomideandradiotherapyinanaggressiveacthpituitaryadenoma AT ozreticdavid arapidbiochemicalandradiologicalresponsetotheconcomitanttherapywithtemozolomideandradiotherapyinanaggressiveacthpituitaryadenoma AT kastelandarko arapidbiochemicalandradiologicalresponsetotheconcomitanttherapywithtemozolomideandradiotherapyinanaggressiveacthpituitaryadenoma AT misirkrpanana rapidbiochemicalandradiologicalresponsetotheconcomitanttherapywithtemozolomideandradiotherapyinanaggressiveacthpituitaryadenoma AT dusektina rapidbiochemicalandradiologicalresponsetotheconcomitanttherapywithtemozolomideandradiotherapyinanaggressiveacthpituitaryadenoma AT rakusiczoran rapidbiochemicalandradiologicalresponsetotheconcomitanttherapywithtemozolomideandradiotherapyinanaggressiveacthpituitaryadenoma AT solakmirsala rapidbiochemicalandradiologicalresponsetotheconcomitanttherapywithtemozolomideandradiotherapyinanaggressiveacthpituitaryadenoma AT kraljevicivana rapidbiochemicalandradiologicalresponsetotheconcomitanttherapywithtemozolomideandradiotherapyinanaggressiveacthpituitaryadenoma AT bisofvesna rapidbiochemicalandradiologicalresponsetotheconcomitanttherapywithtemozolomideandradiotherapyinanaggressiveacthpituitaryadenoma AT ozreticdavid rapidbiochemicalandradiologicalresponsetotheconcomitanttherapywithtemozolomideandradiotherapyinanaggressiveacthpituitaryadenoma AT kastelandarko rapidbiochemicalandradiologicalresponsetotheconcomitanttherapywithtemozolomideandradiotherapyinanaggressiveacthpituitaryadenoma |